Acaster Lloyd Consulting Ltd, London, WC1X 8NL, UK.
Boehringer Ingelheim International GmbH, D-55216 Ingelheim/Rhein, Germany.
J Comp Eff Res. 2024 Feb;13(2):e230033. doi: 10.57264/cer-2023-0033. Epub 2024 Jan 16.
This study estimated utility values for non-alcoholic steatohepatitis (NASH). Previous studies have assumed that health-related quality of life does not vary between the early stages of NASH. Discrete choice experiment (DCE) surveys estimated the value of avoiding fibrosis progression. Patients also completed the EQ-5D-5L. Marginal rates of substitution estimated utility change associated with fibrosis progression. DCE surveys were completed by the UK general public (n = 520) and patients with NASH (n = 154). The utility decline between fibrosis stages F1 and F4 decompensated was between -0.521 to -0.646 (depending on method). Three methods were used to estimate utilities for NASH, each one showed sensitivity to advancing fibrosis, including in the early stages, which is often considered asymptomatic.
本研究评估了非酒精性脂肪性肝炎（NASH）的效用值。既往研究假设，NASH 的早期阶段，健康相关生活质量并无差异。离散选择实验（DCE）调查评估了避免纤维化进展的价值。患者还完成了 EQ-5D-5L 量表。边际替代率估计与纤维化进展相关的效用变化。DCE 调查由英国普通公众（n=520）和 NASH 患者（n=154）完成。纤维化阶段 F1 到 F4 失代偿之间的效用下降在-0.521 到-0.646 之间（取决于方法）。使用三种方法估计 NASH 的效用，每种方法都显示出对纤维化进展的敏感性，包括在早期阶段，通常被认为是无症状的。
